Headache and Migraine

Neurology News Network for the week of December 15, 2018.

The Senior Medical Director at Eli Lilly discussed the clinical impact galcanezumab could have for patients with cluster headache if approved by the FDA.

If you suspect vestibular migraine, you’re not alone. One in 10 patients receive the diagnosis that is often confused with other conditions.

Presenting our year in review, a collection by experts in their respective fields of brain injury, MS, concussion, epilepsy, migraine, and more.

Neurology News Network for the week of December 1, 2018.

The Senior Medical Director of Eli Lilly and Company spoke to lasmiditan and the clinical impact the investigational therapy could have for patients with acute migraine.

The non-invasive vagus nerve stimulator’s OK marks the first approval for cluster headache of any kind.

New research provides insights into migraine with visual aura, cognitive behavioral therapy, and the genetic basis of pediatric migraine.

A 20-year-old woman had a Caesarian section at 39 weeks. She had a history of migraine, but this headache was different. Her request for “something really strong” for the pain was cause for concern.

Neurology News Network for the week of November 24, 2018.

These findings are among the first in the United States to indicate an association between migraine and atrial fibrillation.

The director of the MedStar Georgetown University Hospital Headache Center shared her interest in the pipeline and the ongoing search for biomarkers in migraine.

The director of the MedStar Georgetown Headache Center discussed ways to improve the patient-provider relationship and how primary care can get involved.

An increased risk of this condition in patients with migraine headaches has recently been recognized.

The director of the MedStar Georgetown University Hospital Headache Center stressed building a culture of teaching patients to be their own advocates and to build the relationship with the patient to better manage their migraines.

The director of the MedStar Georgetown University Hospital Headache Center discussed the development of acute care options for patients to improve their quality of life and the management of their condition.

The director of the Hartford Headache Center spoke about the trend toward device use in migraine treatment, and some of the reasons that may have prompted it.

Neurology News Network for the week of November 17, 2018.

The director of the Hartford Healthcare Headache Center in Connecticut and lead investigator on the trial provided some insight into the study's findings.

As the scientific grasp of it gets tighter, ensuring physicians have an understanding of the diagnosis of and treatment options for cluster headache becomes of utmost importance.

Theranica, its developer, noted that it has completed regulatory submission for the device to the FDA, and that if approved, it plans to commercialize the product by the end of 2019.

While studies support the use of cannabis for pain in adults, a lack of clinical data and an inability to perform studies has slowed the medical community’s understanding of the drug’s conceivable use in headache conditions.

Eli Lilly intends to submit a supplemental biologics license application to the FDA for galcanezumab for the preventive treatment of episodic cluster headache by the end of 2018.

This case series appears to identify a new subtype of chronic daily headache in overweight/obese women in their fifties and sixties.

If approved, lasmiditan could represent the first significant innovation for acute treatment of migraine in more than 2 decades.

Recent work demonstrates that the anterior part of the hypothalamus is enlarged in cluster headache.

Your new patient is a 16-year-old high school student who received a diagnosis of chronic migraine two years ago. She has recently become sexually active. How would you counsel this patient?

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals provided insight into how fremanezumab has helped to improve these facets of the condition.

Could 20 years of treatment for migraine have prompted a spontaneous absence of speech after this patient stopped taking her medication?

Neurology News Network for the week of November 3, 2018.